ATE121296T1 - Igf-i zur behandlung von nebeneffekten der steroidtherapie. - Google Patents

Igf-i zur behandlung von nebeneffekten der steroidtherapie.

Info

Publication number: ATE121296T1
Authority: AT; Austria
Prior art keywords: igf; treatment; side effects; steroid therapy; steroid
Prior art date: 1989-12-22

Application number

AT90810987T

Other languages

English (en)

Inventor

Ronald L Goldberg

Original Assignee

Ciba Geigy Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-12-22

Filing date

1990-12-13

Publication date

1995-05-15

1990-12-13 Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag

1995-05-15 Application granted granted Critical

1995-05-15 Publication of ATE121296T1 publication Critical patent/ATE121296T1/de

Links

102000004218 Insulin-Like Growth Factor I Human genes 0.000 title abstract 3
108090000723 Insulin-Like Growth Factor I Proteins 0.000 title abstract 3
230000000694 effects Effects 0.000 title abstract 2
150000003431 steroids Chemical class 0.000 title abstract 2
238000002560 therapeutic procedure Methods 0.000 title 1
230000002411 adverse Effects 0.000 abstract 1
210000000845 cartilage Anatomy 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
230000037314 wound repair Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Toxicology (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Molecular Biology (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)
Medicines Containing Plant Substances (AREA)

AT90810987T 1989-12-22 1990-12-13 Igf-i zur behandlung von nebeneffekten der steroidtherapie. ATE121296T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US45521589A	1989-12-22	1989-12-22

Publications (1)

Publication Number	Publication Date
ATE121296T1 true ATE121296T1 (de)	1995-05-15

Family

ID=23807878

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT90810987T ATE121296T1 (de)	1989-12-22	1990-12-13	Igf-i zur behandlung von nebeneffekten der steroidtherapie.

Country Status (14)

Country	Link
EP (1)	EP0434625B1 (de)
JP (1)	JP2934023B2 (de)
KR (1)	KR100191381B1 (de)
AT (1)	ATE121296T1 (de)
AU (1)	AU641966B2 (de)
CA (1)	CA2032859C (de)
DE (1)	DE69018799T2 (de)
DK (1)	DK0434625T3 (de)
ES (1)	ES2071080T3 (de)
GR (1)	GR3015900T3 (de)
IE (1)	IE67510B1 (de)
IL (1)	IL96711A (de)
NZ (1)	NZ236614A (de)
ZA (1)	ZA9010332B (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5128320A (en) *	1990-01-18	1992-07-07	Genentech, Inc.	Method of restoring normal growth, weight gain or lean body mass in patients with glucocorticoid excess by administering igf-i
TW267102B (de)	1992-03-13	1996-01-01	Ciba Geigy
US5407913A (en) *	1992-12-03	1995-04-18	Celtrix Pharmaceuticals, Inc.	Method and composition for systemic treatment of tissue injury
WO1996007744A1 (en) *	1994-09-08	1996-03-14	Chiron Corporation	A method of improved production of insulin-like growth factor
US5712249A (en) *	1994-09-08	1998-01-27	Ciba-Geigy Corporation	Use of insulin-like growth factors I and II for inhibition of inflammatory response
AU7271996A (en) *	1995-10-23	1997-05-15	Queen's University At Kingston	Method and pharmaceutical composition for chondrostimulation with a prostaglandin (e.g. misoprostol) and tgf-beta, optionally in combination with igf-1
EP0956041A1 (de) *	1996-09-16	1999-11-17	Dalhousie University	Verwendung von igf-1 zur behandlung von polyzystischer nierenkrankheit und damit verbundene indikationen
US6025368A (en) *	1997-02-25	2000-02-15	Celtrix Pharmaceuticals, Inc.	Method for treating the symptoms of chronic stress-related disorders using IGF
US6015786A (en) *	1997-02-25	2000-01-18	Celtrix Pharmaceuticals, Inc.	Method for increasing sex steroid levels using IGF or IGF/IGFBP-3
US6514937B1 (en)	1997-02-25	2003-02-04	Celtrix Pharmaceuticals, Inc.	Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3
AU3548999A (en)	1998-04-03	1999-10-25	Chiron Corporation	Use of igfi for treating articular cartilage disorders
AU762351B2 (en)	1999-01-06	2003-06-26	Genentech Inc.	Insulin-like growth factor (IGF) I mutant variants
AU2001263215A1 (en)	2000-05-16	2001-11-26	Genentech Inc.	Method for treating cartilage disorders
WO2007016620A2 (en)	2005-08-01	2007-02-08	Genera Doo	Methods and compositions for regenerating articular cartilage

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR960005708B1 (ko) *	1986-11-14	1996-05-01	인스티튜트 오브 몰레큘러 바이올로지, 인코오포레이티드	외상 치료 및 뼈 재생용 조성물
SE8703625D0 (sv) *	1987-09-18	1987-09-18	Kabivitrum Ab	New medical use
US4983581A (en) *	1988-05-20	1991-01-08	Institute Of Molecular Biology, Inc.	Wound healing composition of IGF-I and TGF-β

1990
- 1990-12-12 ZA ZA9010332A patent/ZA9010332B/xx unknown
- 1990-12-13 ES ES90810987T patent/ES2071080T3/es not_active Expired - Lifetime
- 1990-12-13 AT AT90810987T patent/ATE121296T1/de not_active IP Right Cessation
- 1990-12-13 DK DK90810987.9T patent/DK0434625T3/da active
- 1990-12-13 EP EP90810987A patent/EP0434625B1/de not_active Expired - Lifetime
- 1990-12-13 DE DE69018799T patent/DE69018799T2/de not_active Expired - Fee Related
- 1990-12-18 IL IL9671190A patent/IL96711A/en not_active IP Right Cessation
- 1990-12-19 AU AU68247/90A patent/AU641966B2/en not_active Ceased
- 1990-12-20 CA CA002032859A patent/CA2032859C/en not_active Expired - Fee Related
- 1990-12-20 KR KR1019900021111A patent/KR100191381B1/ko not_active Expired - Fee Related
- 1990-12-21 JP JP2405132A patent/JP2934023B2/ja not_active Expired - Fee Related
- 1990-12-21 IE IE468490A patent/IE67510B1/en not_active IP Right Cessation
- 1990-12-21 NZ NZ236614A patent/NZ236614A/xx unknown
1995
- 1995-04-20 GR GR950400745T patent/GR3015900T3/el unknown

Also Published As

Publication number	Publication date
ES2071080T3 (es)	1995-06-16
KR100191381B1 (ko)	1999-06-15
IE67510B1 (en)	1996-04-03
DK0434625T3 (da)	1995-06-26
CA2032859A1 (en)	1991-06-23
IL96711A (en)	1996-01-19
JPH04210648A (ja)	1992-07-31
EP0434625A2 (de)	1991-06-26
CA2032859C (en)	2007-09-17
IE904684A1 (en)	1991-07-17
IL96711A0 (en)	1991-09-16
EP0434625A3 (en)	1991-10-02
AU6824790A (en)	1991-06-27
NZ236614A (en)	1993-10-26
ZA9010332B (en)	1991-08-28
DE69018799D1 (de)	1995-05-24
EP0434625B1 (de)	1995-04-19
KR910011279A (ko)	1991-08-07
AU641966B2 (en)	1993-10-07
JP2934023B2 (ja)	1999-08-16
GR3015900T3 (en)	1995-07-31
DE69018799T2 (de)	1995-09-21

Legal Events

Date	Code	Title	Description
1995-10-15	UEP	Publication of translation of european patent specification
2009-09-15	REN	Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
DE69018799D1 (de)	1995-05-24	IGF-I zur Behandlung von Nebeneffekten der Steroidtherapie.
DE69016768D1 (de)	1995-03-23	Zusammensetzung und Verfahren für die Behandlung von Osteoporose bei Säugetieren.
ATE187889T1 (de)	2000-01-15	Vorbeugung und behandlung der peripheren neuropathie
ATE186840T1 (de)	1999-12-15	Zusammensetzungen und methoden zur wundbehandlung
DK0429570T3 (da)	1998-04-27	Osteoinducerende præparater
DE3779149D1 (de)	1992-06-25	Galanthamin oder dessen analoge zur behandlung der alzheimerschen krankheit.
GR3004582T3 (de)	1993-04-28
DE59510705D1 (de)	2003-07-03	Zusammensetzungen zur behandlung von irds und ards, die mindestens ein glucocorticosteroid in kombination mit einem lungen surfactant enthalten
DE69228118D1 (de)	1999-02-18	Bmp-9 zusammensetzungen
EP0675723A4 (de)	1998-08-05	Biphosphonat/östrogen-therapie zur behandlung und prävention von knochenverlust.
ATE107515T1 (de)	1994-07-15	Zusammensetzung zur behandlung von entzündung.
DE69509843D1 (de)	1999-07-01	Apparat zur Behandlung z.B. von Poststücken
DE3851584D1 (de)	1994-10-27	Gegen Allergie wirkende Benzothiophene und neue und andere ausgewählte Benzothiophene, beide mit Wirkung zur Behandlung von akuten Atmungsangstanzeichen.
ATE178206T1 (de)	1999-04-15	Verfahren zur vorbeugung und behandlung von durch chemotherapie ausgelöster alopezie
DE69431199D1 (de)	2002-09-26	Melatonin-Derivate zur Verwendung in der Behandlung von Schlafstörungen
DE69301750D1 (de)	1996-04-18	Verwendung von 1-Alpha,24(R)-Dihydroxy-22(E)-Dehydrovitamin-D3 zur Herstellung eines Arzneimittels zur Behandlung der Osteoporose
ATE110961T1 (de)	1994-09-15	Behandlung von beatmungsabhängigkeit mit wachstumshormon.
DE69000960D1 (de)	1993-04-01	Zusammensetzung zur behandlung von pigmentierung.
ATE178336T1 (de)	1999-04-15	Verwendung einer therapeutischen zusammensetzung zur behandlung von bronchitis
DE68905602D1 (de)	1993-04-29	Verfahren zur behandlung von titanstrukturen.